HLA and HIV-1: Heterozygote Advantage and B*35-Cw*04 Disadvantage

M Carrington, GW Nelson, MP Martin, T Kissner… - Science, 1999 - science.org
M Carrington, GW Nelson, MP Martin, T Kissner, D Vlahov, JJ Goedert, R Kaslow…
Science, 1999science.org
A selective advantage against infectious disease associated with increased heterozygosity
at the human major histocompatibility complex [human leukocyte antigen (HLA) class I and
class II] is believed to play a major role in maintaining the extraordinary allelic diversity of
these genes. Maximum HLA heterozygosity of class I loci (A, B, and C) delayed acquired
immunodeficiency syndrome (AIDS) onset among patients infected with human
immunodeficiency virus–type 1 (HIV-1), whereas individuals who were homozygous for one …
A selective advantage against infectious disease associated with increased heterozygosity at the human major histocompatibility complex [human leukocyte antigen (HLA) class I and class II] is believed to play a major role in maintaining the extraordinary allelic diversity of these genes. Maximum HLA heterozygosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among patients infected with human immunodeficiency virus–type 1 (HIV-1), whereas individuals who were homozygous for one or more loci progressed rapidly to AIDS and death. The HLA class I alleles B*35 andCw*04 were consistently associated with rapid development of AIDS-defining conditions in Caucasians. The extended survival of 28 to 40 percent of HIV-1–infected Caucasian patients who avoided AIDS for ten or more years can be attributed to their being fully heterozygous at HLA class I loci, to their lacking the AIDS-associated alleles B*35 and Cw*04, or to both.
AAAS